Patient P-03390

Synthetic patientONX-7 · Day 138 · 45–54 · F · baseline S14Open companion preview

Therapy response

Unstable

Tolerance

Deteriorating

GI state

Unstable

Inflammatory state

Unstable

Nutritional resilience

Unstable

Discontinuation risk

96%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 ONX-7 started — Baseline state S14
Day 59 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 73 ME-01 recommended — Monitoring Escalation ME-01
Day 74 Patient accepted — Started ME-01 in the companion
Day 77 Deterioration detected before clinical escalation — Monitoring Escalation ME-01

What changed?

Trajectory began diverging from predicted response on Day 59.

Primary contributors, last 14 days

Toxicity+13
GI instability-10
Nutritional resilience+9
Inflammatory activity-4
Treatment adherence-3

What helped?

Monitoring Escalation ME-01Day 73
Result: deterioration detected before clinical escalation

LIFE OS recommendation

GI Support Protocol GI-04

90%

probability of meaningful tolerance improvement

284 similar trajectories
82% showed improvement
median effect visible after 8 days

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 30/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
Autonomic recovery ↑65
- WearableResting HR 79 bpm
- Wearable1,792 steps/day
- WearableShort sleep window
Mucosal barrier integrity ↓60
- DNAFUT2 non-secretor lowers mucosal fucosylation
- Daily logGI symptom score 70 and rising
- WearableSleep 4.6 h, below personal baseline
Inflammatory signalling ↓60
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 60
- WearableHRV 27 ms, trending down
Drug metabolism and exposure ↑20
- BloodToxicity index 53

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
CYP2D6 Normal metabolizer
Expected exposure

Microbiome

Shannon diversity 2.6 · butyrate capacity 30/100

Akkermansia muciniphilaNormal
Faecalibacterium prausnitziiLow
Bacteroides fragilisHigh
Bifidobacterium longumLow
EnterobacteriaceaeHigh

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 26 ms
Sleep: 5.0 h
Steps: 2,312
Resting HR: 79 bpm

Daily log: GI score 70, nutritional resilience 42, adherence 42.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Avoid known triggers for now: fried or oily food, dairy, alcohol

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
A 15-minute walk after lunch
Protect a 7.5-hour sleep window; screens off 30 minutes before
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the scheduled dose as agreed with your care team
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-03341	50%	S14	NP-02	improved	49
P-03049	47%	S14	GI-04	improved	49
P-03323	47%	S14	GI-04	improved	48
P-03293	46%	S14	GI-04	no change	41
P-03037	45%	S14	NP-02	improved	43
P-03030	42%	S14	NP-02	improved	43
P-03345	42%	S14	SC-12	improved	56
P-03081	41%	S10	GI-04	improved	53
P-03413	38%	S14	ME-01	improved	48
P-03460	37%	S11	SC-12	improved	46
P-03430	35%	S14	SC-12	improved	45
P-03151	34%	S18	—	—	51